Skip to content
July 01, 2022

Equity.Guru

Investment information for the new generation

FH.NEO

Filament Health (FH.E) inked a supply deal with Optimi Health (OPTI.C) for psilocybin mushrooms for testing and analysis by Filament’s research team. These mushrooms come at the behest of…
Our Psychedelic Trip Isn’t Over   I don’t know the first thing about psychedelics. Rather, that’s what I would have been saying back in 2020 when the psychedelics sector…
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public…
It has been awhile since I talked about Filament Health and the psychedelics sector in general. In my last post, I left readers in suspense as I shared a…
Counting to Four $25.537M Market Capitalization  Filament Health Corp. (FH.NE) announced today that it has been issued a fourth patent for the extraction and standardization of natural psilocybin and…
Natural Psychedelics Revolution $21.418M Market Capitalization Filament Health Corp. (FH.NE) announced today that it has entered into an exclusive licensing agreement with Psyence Group Inc. (PSYG.C). Under the terms…
Patent Issuance $18.123M Market Capitalization Filament Health Corp. (FH.NE) announced today that it has been issued a patent by the United States Patent and Trademark Office (USPTO) for the…
Meeting with the FDA   $18.123M Market Capitalization Filament Health Corp. (FH.NE) announced today that it has held a pre-investigational new drug application (PIND) meeting with the FDA Division…
A Transformative Year $18.123M Market Capitalization Filament Health Corp. (FH.NE) today released its Q4 2021 financial results and has provided operational highlights for the period ended December 31, 2021….
Natural Talent Albert Hofmann was a fun guy, pun intended. More importantly, the Swiss chemist is known for being the first person to synthesize, consume, and learn of the psychedelic…